{"mcpName":"station__algovigilance__microgram-fda-abuse-deterrent-eval","slug":"algovigilance__microgram-fda-abuse-deterrent-eval","label":"Microgram: fda-abuse-deterrent-eval","description":"FDA abuse-deterrent opioid evaluation: routes by formulation properties and abuse pathway per FDA Guidance 'Abuse-Deterrent Opioids - Evaluation and Labeling' (2015)","domainSlug":"algovigilance","pvRelevance":"pv-core","backend":"native","agentMetadata":{"idempotent":true,"read_only":true,"expected_latency_ms":null,"cost_tokens_estimate":null,"pipes_to":null},"inputSchema":{"type":"object","properties":{"abuse_pathway":{"type":"string","description":"Route of abuse: oral_excessive, intranasal, injection, smoking, combined"},"formulation_category":{"type":"string","description":"Abuse-deterrent category: physical_chemical_barrier, agonist_antagonist, aversion, delivery_system, prodrug, combination"},"in_vitro_result":{"type":"string","description":"In vitro manipulation study result: resistant, partially_resistant, not_resistant"},"clinical_abuse_study":{"type":"boolean","description":"Whether clinical abuse potential study (Category 3) has been completed"}},"required":["abuse_pathway","formulation_category"],"additionalProperties":false},"example":null,"taxonomy":{"rank":{"domain":"Substrata","kingdom":"Constructa","phylum":"Configa","class":"station-config","order":"algovigilance","family":"mcp-tool-config"},"characteristics":{"substrate":"config","domain":"pv","lifecycle":"continuous","stateful":false,"persistence":"none","authority":"read","compounding":"producer","io_input":"agent-request","io_output":"tool-response"}},"_links":{"html":"/tools/algovigilance__microgram-fda-abuse-deterrent-eval","markdown":"/tools/algovigilance__microgram-fda-abuse-deterrent-eval/raw.md","invoke":"/api/mcp","catalog":"/api/mcp"}}